Olutasidenib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 150 mg
Reference Brands: Rezlidhia (USA)
Category:
Oncology Cancer Care
Olutasidenib is available in Capsules
and strengths such as 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Olutasidenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Olutasidenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Olutasidenib, marketed under the brand name Rezlidhia, is an oral targeted anticancer therapy used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. It belongs to a class of precision oncology drugs designed to address the underlying genetic drivers of certain cancers.
Olutasidenib works by selectively inhibiting the mutant IDH1 enzyme, which is responsible for producing the oncometabolite 2-hydroxyglutarate (2-HG). Elevated levels of 2-HG disrupt normal cellular differentiation and contribute to the development and progression of leukemia. By reducing 2-HG production, olutasidenib helps restore normal cell maturation and suppress the growth of malignant leukemic cells.
Administered orally, Rezlidhia offers a convenient treatment option for patients who have limited therapeutic alternatives after disease relapse or resistance to prior therapies. The drug represents an important advancement in personalized cancer treatment, as it is specifically indicated for patients whose tumors harbor an IDH1 mutation. Through its targeted mechanism of action, olutasidenib provides a focused approach to managing AML while minimizing effects on non-mutated cells, supporting improved disease control and patient outcomes.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing